COMPANY PROFILES

IBA is your worldwide innovation leader in the field of proton therapy with future technologies such as DynamicARC® and ConformalFLASH® on our Proteus® platform.

Thanks to our innovative mindset, we have remained ahead of the curve and built the largest community of proton therapy users who have treated more than 140,000 patients globally.

Together we form the most knowledgeable proton therapy community in the world. We are not mere providers, we are real partners.

RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment.

RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*.

The most recent additions to the RaySearch product line are RayIntelligence®.

RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data.

Baptist Health is the largest healthcare organization in the region, with 12 hospitals, more than 28,000 employees, 4,000 physicians and 200 outpatient centers, urgent care facilities and physician practices across South Florida.

Its institutes are internationally renowned in cancer, brain and spine, heart and vascular, and orthopedic care.

A not-for-profit organization supported by philanthropy, Baptist Health is an academic and clinical affiliate of Florida International University’s Herbert Wertheim College of Medicine and has been recognized by Fortune and U.S.

News as one of the nation’s best healthcare systems and workplaces.

BioProtect is a technology platform company that provides innovative biodegradable spacing solutions. Currently commercially available is our BioProtect Balloon, which addresses radiation-induced rectal toxicity in prostate cancer patients. 

Our vision is to become a world leader in spacing technology and to protect healthy organs during radiation therapy treatment. 

BioProtect’s first application, the BioProtect Balloon Implant System, is commercially available in Europe and in the US. 

BioProtect is ISO 13485:2016 certified, FDA cleared, and CE marked. 

CQ Medical is the global leader in developing high-quality, innovative, patient-centric radiotherapy and cancer therapy solutions.

Our company has more than 80 years of combined experience bringing advanced hardware and consumables for patient immobilization and positioning, fiducial markers, couchtops, and patient care products to the market.

CQ Medical is the designer and manufacturer of the market-leading kVue™ BoS®, kVue Pronumbra, and Universal Couchtop™ ProForm™ Head & Neck Positioning Systems.

From researchers and scientists to designers and developers, CQ Medical is at the forefront of cutting-edge medical technology designed to deliver the best possible outcomes.

Gold Anchor is a fiducial marker for any soft tissue with proven clinical benefits.

For proton therapy, Gold Anchor offers the following unique combination of benefits compared to alternatives:

• Low dose perturbation due to the thin marker diameter.
• Great kV-visibility compared to low density markers such as polymer or carbon markers.
• Enhanced MR-visibility due to the unique and patented marker material, an alloy of gold and iron.
• Industry-leading thin needle - 25G, 22G or 20G for Gold Anchor compared to 17G or 18G for most alternatives.

Anchoring marker design, allowing imaging for dose planning on the same day as implantation.

Hitachi is the leading particle therapy system provider worldwide.

With decades of experience in radiation therapy, Hitachi delivers reliable proton, carbon-ion, and hybrid systems.

By incorporating an upright patient positioning system, Hitachi also offers compact treatment solutions that combine robustness and innovation.

From design and construction to long-term operation and maintenance, Hitachi enables partners to choose the best treatment options that fit their needs.

The official journal of the Particle Therapy Co-Operative Group (PTCOG), disseminates the most up-to-date information on the clinical, physical, and biological research in proton, light-ion, and heavy charged-particle therapy.

IJPT, published by Elsevier on behalf of PTCOG, is open access and welcomes original articles, reviews, case reports, letters to the Editor, and technical notes.

Visit Sciencedirect to learn more.

Mevion Medical Systems is the leading provider of compact proton therapy systems for cancer care.

Dedicated to advancing the design and accessibility of proton therapy worldwide, Mevion pioneered the single-room platform and continues to further the science and application of proton therapy.

Since 2013, Mevion compact proton therapy single-room systems have been used by leading cancer centers for treating patients.

Mevion’s series of products, including the flagship MEVION S250i and MEVION S250-FIT with HYPERSCAN pencil beam scanning, represent the world’s most compact proton therapy systems that eliminate the obstacles of size, complexity, and cost.

Mevion is headquartered in Littleton, Massachusetts with a presence in Europe and Asia.

For more information, please visit www.mevion.com.

Orfit brings high precision and comfort to the positioning and immobilization in proton therapy thanks to devices that perfectly pair with advanced delivery techniques.

The Aerial® proton couch top optimizes the impact of the proton dose.

Combined with HP PRO® masks we bring more comfort to the patient while safeguarding stability and reproducibility. 

Founded in 2007, P-Cure is at the forefront of democratizing Proton Therapy, offering the most compact FDA-cleared solution for treating cancer patients. P-Cure's comprehensive system enables the planning and treatment of patients with Proton Therapy in both supine and seated positions, fitting linac-like vaults within existing/new radiation therapy centers.

• Operating globally with production, service, and R&D platforms in the US, Israel, and China, P-Cure collaborates closely with healthcare providers supporting them in achieving unprecedented return on investment with operating breakeven typically within a year of implementation.
• P-Cure is dedicated to ushering in a new era of life-saving technology accessible to all oncology centers and their patients, revolutionizing the cancer treatment landscape worldwide.

Proton Collaborative Group (PCG) is committed to improving the outcomes of cancer patients by working collectively to advance the role of particle radiotherapy in cancer treatment.

PCG serves as the link between state-of-the-art treatment centers, expert physicians, innovative and high-quality collaborative research, and the largest and most comprehensive proton therapy database in the world.

RAD provides design-built modular facilities for the healthcare industry including radiotherapy vaults and clinics, proton vaults and clinics, and other specialty healthcare facilities.

Our customized, factory fabricated solutions are completed up to 50% faster than standard construction and are installed for temporary, interim or permanent use.

RAD’s Operating Leases require no capital, allowing projects to commence and complete sooner and customers to generate revenue faster.

The Radiation Oncology Department at St. Jude Children’s Research Hospital is dedicated to the research and treatment of pediatric patients, focusing on investigator-initiated clinical trials and innovative approaches to treatment planning, delivery, and outcome modeling with photon and proton therapy.

The department supports the St. Jude–IAEA partnership to address global inequalities in childhood cancer care.

The team includes physicists, dosimetrists, research staff, and pediatric radiation oncologists, supported by nursing, therapy, and child life specialists.

The St. Jude Proton Therapy Center, the only facility worldwide exclusively for children, features two gantry rooms, a fixed beam room, comprehensive imaging, anesthesia support, and treats about 300 children, adolescents, and young adults annually.

Varian has long been on a mission to help create a world without fear of cancer.

Now, as a Siemens Healthineers company, we are working as one, based on a more expansive perspective of the patient's journey than ever before.

As a result, our vision for the future – and what we can achieve on behalf of patients – has expanded and become much more comprehensive.

Given the broad portfolio of imaging and cancer care technologies and services that we offer as one unified company, we are working together to create an oncology ecosystem that enables us to support care providers along the entire cancer care continuum.

The Decipher Prostate Genomic Classifier by Veracyte provides prognostic information to assess patients' individual risk.

It has been validated in over 95 studies as the most accurate predictor of metastasis, prostate cancer-specific mortality, and overall survival.